311 related articles for article (PubMed ID: 29925684)
1. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.
Dykens EM; Miller J; Angulo M; Roof E; Reidy M; Hatoum HT; Willey R; Bolton G; Korner P
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925684
[TBL] [Abstract][Full Text] [Related]
2. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
[TBL] [Abstract][Full Text] [Related]
3. Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.
Damen L; Grootjen LN; Juriaans AF; Donze SH; Huisman TM; Visser JA; Delhanty PJD; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2021 May; 94(5):774-785. PubMed ID: 33296519
[TBL] [Abstract][Full Text] [Related]
4. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial.
Hollander E; Levine KG; Ferretti CJ; Freeman K; Doernberg E; Desilva N; Taylor BP
J Psychiatr Res; 2021 May; 137():643-651. PubMed ID: 33190843
[TBL] [Abstract][Full Text] [Related]
5. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
6. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
Strong TV; Miller JL; McCandless SE; Gevers E; Yanovski JA; Matesevac L; Bohonowych J; Ballal S; Yen K; Hirano P; Cowen NM; Bhatnagar A
J Neurodev Disord; 2024 Apr; 16(1):22. PubMed ID: 38671361
[TBL] [Abstract][Full Text] [Related]
7. Transcranial direct current stimulation reduces food-craving and measures of hyperphagia behavior in participants with Prader-Willi syndrome.
Bravo GL; Poje AB; Perissinotti I; Marcondes BF; Villamar MF; Manzardo AM; Luque L; LePage JF; Stafford D; Fregni F; Butler MG
Am J Med Genet B Neuropsychiatr Genet; 2016 Mar; 171B(2):266-75. PubMed ID: 26590516
[TBL] [Abstract][Full Text] [Related]
8. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.
Miller JL; Tamura R; Butler MG; Kimonis V; Sulsona C; Gold JA; Driscoll DJ
Am J Med Genet A; 2017 May; 173(5):1243-1250. PubMed ID: 28371242
[TBL] [Abstract][Full Text] [Related]
9. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
[TBL] [Abstract][Full Text] [Related]
10. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.
Kuppens RJ; Donze SH; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2016 Dec; 85(6):979-987. PubMed ID: 27486141
[TBL] [Abstract][Full Text] [Related]
11. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
[TBL] [Abstract][Full Text] [Related]
12. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
Kimonis V; Surampalli A; Wencel M; Gold JA; Cowen NM
PLoS One; 2019; 14(9):e0221615. PubMed ID: 31545799
[TBL] [Abstract][Full Text] [Related]
13. A disease specific questionnaire for assessing behavior in individuals with Prader-Willi syndrome.
Avrahamy H; Pollak Y; Shriki-Tal L; Genstil L; Hirsch HJ; Gross-Tsur V; Benarroch F
Compr Psychiatry; 2015 Apr; 58():189-97. PubMed ID: 25677112
[TBL] [Abstract][Full Text] [Related]
14. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome.
Einfeld SL; Smith E; McGregor IS; Steinbeck K; Taffe J; Rice LJ; Horstead SK; Rogers N; Hodge MA; Guastella AJ
Am J Med Genet A; 2014 Sep; 164A(9):2232-9. PubMed ID: 24980612
[TBL] [Abstract][Full Text] [Related]
15. Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling.
Tsai JH; Scheimann AO; McCandless SE; Strong TV; Bridges JFP
J Med Econ; 2018 Dec; 21(12):1230-1237. PubMed ID: 30256699
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
Tan Q; Orsso CE; Deehan EC; Triador L; Field CJ; Tun HM; Han JC; Müller TD; Haqq AM
Obes Rev; 2020 May; 21(5):e12992. PubMed ID: 31889409
[TBL] [Abstract][Full Text] [Related]
17. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
[TBL] [Abstract][Full Text] [Related]
18. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
Miller JL; Gevers E; Bridges N; Yanovski JA; Salehi P; Obrynba KS; Felner EI; Bird LM; Shoemaker AH; Angulo M; Butler MG; Stevenson D; Abuzzahab J; Barrett T; Lah M; Littlejohn E; Mathew V; Cowen NM; Bhatnagar A;
J Clin Endocrinol Metab; 2023 Jun; 108(7):1676-1685. PubMed ID: 36639249
[TBL] [Abstract][Full Text] [Related]
19. Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment.
Höybye C; Barkeling B; Espelund U; Petersson M; Thorén M
Growth Horm IGF Res; 2003 Dec; 13(6):322-7. PubMed ID: 14624765
[TBL] [Abstract][Full Text] [Related]
20. Assessment of hyperphagia in Prader-Willi syndrome.
Dykens EM; Maxwell MA; Pantino E; Kossler R; Roof E
Obesity (Silver Spring); 2007 Jul; 15(7):1816-26. PubMed ID: 17636101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
